Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 302, Issue 9, 2012, Pages

  McLaughlin, Patricia J ^a   Keiper, Cara L ^a   Verderame, Michael F ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cornea; DNA synthesis; Opioid growth factor; Opioids; Skin

Indexed keywords

CYTOKERATIN 5; DNA; GROWTH FACTOR RECEPTOR; OPIATE PEPTIDE; OPIOID GROWTH FACTOR RECEPTOR; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CORNEA; DOWN REGULATION; EPIDERMIS; EPITHELIUM; FEMALE; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TONGUE; TRANSGENIC MOUSE; WILD TYPE; WOUND HEALING;

ANIMALS; EPITHELIUM; MICE; MICE, TRANSGENIC; OPIOID PEPTIDES; RECEPTORS, OPIOID; SKIN PHYSIOLOGICAL PHENOMENA; UP-REGULATION; WOUND HEALING;

EID: 84860534832     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00670.2011     Document Type: Article

References (43)

1. Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol 298: R459-R466, 2010.
2. Bisignani GJ, McLaughlin PJ, Ordille SD, Jarowenko MJ, Zagon IS. Human renal cell proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 162: 2186-2191, 1999.
3. Blebea J, Mazo JE, Kihara TK, Vu JH, McLaughlin PJ, Atnip RH, Zagon IS. Opioid growth factor modulates angiogenesis. J Vasc Surg 32: 364-373 2000.
4. Cheng F, McLaughlin PJ, Banks WA, Zagon IS. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol 299: R774-R785, 2010.
5. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 7: 5-17, 2007.
6. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 1: 319-327, 2009.
7. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med (Maywood) 234: 532-541, 2009.
8. Cheng F, McLaughlin PJ, Zagon IS. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin β and Ran for nucleocytoplasmic trafficking. Exp Biol Med (Maywood) 235: 1093-1101, 2010.
9. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res 67: 10511-10518, 2007.
10. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol 296: R1716-R1725, 2009.
11. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236: 1036-1050, 2011.
12. Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol 122: 382-388, 2011.
13. Donahue RN, Zagon IS, McLaughlin PJ. The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition. J Cancer Ther 2: 110-124, 2011.
14. Donahue RN, McLaughlin PJ, Zagon IS. Overexpression of the opioid growth factor receptor (OGFr) in human ovarian cancer cells downregulates cell proliferation in vitro and inhibits tumorigenesis in mice. J Cancer Ther 4: 579-594, 2011.
15. Donahue RN, McLaughlin PJ, Zagon IS. Low dose naltrexone (LDN) targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: Mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236: 1036-1050, 2011.
16. Feith DJ, Shantz LM, Pegg AE. Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis. Cancer Res 61: 6073-6081, 2001.
17. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488-501, 2003.
18. Hogan B, Beddington R, Constantini F, Lacy E (Eds.). Manipulating the Mouse Embryo, 2nd ed. Plainview, NY: Cold Spring Harbor Laboratory Press, 1994.
19. McLaughlin PJ, Kreiner S, Morgan CR, Zagon IS. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor (OGFr). Int J Oncol 4: 751-757, 2008.
20. McLaughlin PJ, Pothering CA, Immonen JA, Zagon IS. Topical naltrexone, an opioid antagonist, enhances closure of full-thickness wounds in diabetic rats. Exp Biol Med (Maywood) 236: 1122-1132, 2011.
21. McLaughlin PJ, Stucki J, Zagon IS. Modulation of the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck. Head Neck In press.
22. McLaughlin PJ, Verderame MF, Hankins J, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med 19: 421-428, 2007.
23. Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. Brain Res 1381: 243-253, 2011.
24. Smith JP, Bingaman SI, Mauger DT, Harvey HA, Demers LM, Zagon IS. Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials 2: 37-48, 2010.
25. Smith JP, Bingaman SI, Ruggerio F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: A randomized placebo-controlled trial. Dig Dis Sci 56: 2088-2097, 2011.
26. Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anti-Cancer Drugs 15: 203-209, 2004.
27. Smith JP, Stock H, Bingaman S, Mauger DT, Zagon IS. Low dose naltrexone therapy improves Crohn's disease. Am J Gastroenterol 102: 820-828, 2007.
28. Uehara A, Fujimoto Y, Kawasaki A, Kusumoto S, Fukase K, Takada H. Meso-diaminopimelic acid and meso-lanthionine, amino acids specific to bacterial peptidoglycans, activate human epithelial cells through NOD1. J Immunol 177: 1796-1804, 2006.
29. Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 216: 579-590, 2011.
30. Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 216: 173-183, 2011.
31. Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 297: R1154-R1161, 2009.
32. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood) 8: 968-979, 2008.
33. Zagon IS, Essis FM, Verderame MF, Healy DA, Atnip RG, McLaughlin PJ. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg 37: 636-643, 2003.
34. Zagon IS, Kreiner S, Heslop JJ, Conway AB, Morgan CR, McLaughlin PJ. Prevention and delay in progression of human pancreatic cancer by overexpression of the opioid growth factor receptor (OGFr). Int J Mol Med 33: 317-323, 2008.
35. Zagon IS, McLaughlin PJ. Production and characterization of polyclonal and monoclonal antibodies to the zeta (zeta) opioid receptor. Brain Res 630: 295-302, 1993.
36. Zagon IS, Ruth TB, McLaughlin PJ. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat Rec 282A: 24-37, 2005.
37. Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol 124: 1620-1624, 2006.
38. Zagon IS, Sassani JW, Verderame MF, McLaughlin PJ. Particlemediated gene transfer of OGFr cDNA regulates cell proliferation of the corneal epithelium. Cornea 24: 614-619, 2005.
39. Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal location, and function of a cDNA encoding the opioid growth factor receptor (OGFr) in humans. Brain Res 856: 75-83, 2000.
40. Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, expression, and function of a cDNA encoding a receptor for the opioid growth factor, [Met5]-enkephalin. Brain Res 849: 147-154, 1999.
41. Zagon IS, Verderame MF, Hankins JL, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol 30: 775-783, 2007.
42. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 38: 351-376, 2002.
43. Zagon IS, Verderame MF, Zimmer WE, McLaughlin PJ. Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse. Mol Brain Res 84: 106-114, 2000.